Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.

Kankanala J, Ribeiro CJA, Kiselev E, Ravji A, Williams J, Xie J, Aihara H, Pommier Y, Wang Z.

J Med Chem. 2019 May 9;62(9):4669-4682. doi: 10.1021/acs.jmedchem.9b00274. Epub 2019 Apr 30.

PMID:
30998359
2.

Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.

Tang J, Do HT, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Parniak MA, Sarafianos SG, Wang Z.

Eur J Med Chem. 2019 Mar 15;166:390-399. doi: 10.1016/j.ejmech.2019.01.081. Epub 2019 Feb 2.

PMID:
30739822
3.

5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors.

Tang J, Huber AD, Pineda DL, Boschert KN, Wolf JJ, Kankanala J, Xie J, Sarafianos SG, Wang Z.

Eur J Med Chem. 2019 Feb 15;164:179-192. doi: 10.1016/j.ejmech.2018.12.047. Epub 2018 Dec 21.

PMID:
30594676
4.

Triazolopyrimidine and triazolopyridine scaffolds as TDP2 inhibitors.

Ribeiro CJA, Kankanala J, Xie J, Williams J, Aihara H, Wang Z.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):257-261. doi: 10.1016/j.bmcl.2018.11.044. Epub 2018 Nov 22.

PMID:
30522956
5.

6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H.

Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Parniak MA, Sarafianos SG, Wang Z.

Eur J Med Chem. 2018 Aug 5;156:680-691. doi: 10.1016/j.ejmech.2018.07.035. Epub 2018 Jul 17.

6.

6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.

Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Xie J, Parniak MA, Sarafianos SG, Wang Z.

Eur J Med Chem. 2018 Aug 5;156:652-665. doi: 10.1016/j.ejmech.2018.07.039. Epub 2018 Jul 17.

7.

Hydroxypyridonecarboxylic Acids as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Kankanala J, Wang Y, Geraghty RJ, Wang Z.

ChemMedChem. 2018 Aug 20;13(16):1658-1663. doi: 10.1002/cmdc.201800283. Epub 2018 Jul 20.

PMID:
29968426
8.

The substrate-binding cap of the UDP-diacylglucosamine pyrophosphatase LpxH is highly flexible, enabling facile substrate binding and product release.

Bohl TE, Ieong P, Lee JK, Lee T, Kankanala J, Shi K, Demir Ö, Kurahashi K, Amaro RE, Wang Z, Aihara H.

J Biol Chem. 2018 May 25;293(21):7969-7981. doi: 10.1074/jbc.RA118.002503. Epub 2018 Apr 6.

9.

New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Ribeiro CJA, Kankanala J, Shi K, Kurahashi K, Kiselev E, Ravji A, Pommier Y, Aihara H, Wang Z.

Eur J Pharm Sci. 2018 Jun 15;118:67-79. doi: 10.1016/j.ejps.2018.03.021. Epub 2018 Mar 21.

10.

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.

Kankanala J, Kirby KA, Huber AD, Casey MC, Wilson DJ, Sarafianos SG, Wang Z.

Eur J Med Chem. 2017 Dec 1;141:149-161. doi: 10.1016/j.ejmech.2017.09.054. Epub 2017 Sep 28.

11.

Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.

Vernekar SKV, Tang J, Wu B, Huber AD, Casey MC, Myshakina N, Wilson DJ, Kankanala J, Kirby KA, Parniak MA, Sarafianos SG, Wang Z.

J Med Chem. 2017 Jun 22;60(12):5045-5056. doi: 10.1021/acs.jmedchem.7b00440. Epub 2017 May 31.

12.

Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.

Wang Y, Mao L, Kankanala J, Wang Z, Geraghty RJ.

J Virol. 2017 Jan 18;91(3). pii: e02152-16. doi: 10.1128/JVI.02152-16. Print 2017 Feb 1.

13.

3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.

Wu B, Tang J, Wilson DJ, Huber AD, Casey MC, Ji J, Kankanala J, Xie J, Sarafianos SG, Wang Z.

J Med Chem. 2016 Jul 14;59(13):6136-48. doi: 10.1021/acs.jmedchem.6b00040. Epub 2016 Jun 17.

14.

Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.

Marchand C, Abdelmalak M, Kankanala J, Huang SY, Kiselev E, Fesen K, Kurahashi K, Sasanuma H, Takeda S, Aihara H, Wang Z, Pommier Y.

ACS Chem Biol. 2016 Jul 15;11(7):1925-33. doi: 10.1021/acschembio.5b01047. Epub 2016 May 11.

PMID:
27128689
15.

Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H.

Kankanala J, Kirby KA, Liu F, Miller L, Nagy E, Wilson DJ, Parniak MA, Sarafianos SG, Wang Z.

J Med Chem. 2016 May 26;59(10):5051-62. doi: 10.1021/acs.jmedchem.6b00465. Epub 2016 Apr 29.

16.

Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2).

Kankanala J, Marchand C, Abdelmalak M, Aihara H, Pommier Y, Wang Z.

J Med Chem. 2016 Mar 24;59(6):2734-46. doi: 10.1021/acs.jmedchem.5b01973. Epub 2016 Mar 7.

PMID:
26910725
17.

Identification of Receptor Tyrosine Kinase Inhibitors Using Cell Surface Biotinylation and Affinity Isolation.

Latham AM, Kankanala J, Fishwick CW, Ponnambalam S.

Methods Mol Biol. 2015;1332:121-31. doi: 10.1007/978-1-4939-2917-7_8.

PMID:
26285749
18.

5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus.

Vernekar SK, Qiu L, Zhang J, Kankanala J, Li H, Geraghty RJ, Wang Z.

J Med Chem. 2015 May 14;58(9):4016-28. doi: 10.1021/acs.jmedchem.5b00327. Epub 2015 May 4.

19.

Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities.

Vernekar SK, Liu Z, Nagy E, Miller L, Kirby KA, Wilson DJ, Kankanala J, Sarafianos SG, Parniak MA, Wang Z.

J Med Chem. 2015 Jan 22;58(2):651-64. doi: 10.1021/jm501132s. Epub 2014 Dec 30.

20.

In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.

Latham AM, Kankanala J, Fearnley GW, Gage MC, Kearney MT, Homer-Vanniasinkam S, Wheatcroft SB, Fishwick CW, Ponnambalam S.

PLoS One. 2014 Nov 13;9(11):e110997. doi: 10.1371/journal.pone.0110997. eCollection 2014.

21.

Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.

Foster TL, Thompson GS, Kalverda AP, Kankanala J, Bentham M, Wetherill LF, Thompson J, Barker AM, Clarke D, Noerenberg M, Pearson AR, Rowlands DJ, Homans SW, Harris M, Foster R, Griffin S.

Hepatology. 2014 Feb;59(2):408-22. doi: 10.1002/hep.26685. Epub 2013 Dec 24.

22.

A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Kankanala J, Latham AM, Johnson AP, Homer-Vanniasinkam S, Fishwick CW, Ponnambalam S.

Br J Pharmacol. 2012 May;166(2):737-48. doi: 10.1111/j.1476-5381.2011.01801.x.

23.

Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells.

Latham AM, Bruns AF, Kankanala J, Johnson AP, Fishwick CW, Homer-Vanniasinkam S, Ponnambalam S.

Br J Pharmacol. 2012 Jan;165(1):245-59. doi: 10.1111/j.1476-5381.2011.01545.x.

Supplemental Content

Loading ...
Support Center